{"abstract":"The National Heart, Lung and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), both of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive patent license to Inversago Pharma Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/11/06/2020-24616.html","cfr_references":[],"citation":"85 FR 71079","comment_url":null,"comments_close_on":"2020-11-23","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before November 23, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-24616","effective_on":null,"end_page":71080,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/11/06/2020-24616.xml","html_url":"https://www.federalregister.gov/documents/2020/11/06/2020-24616/prospective-grant-of-exclusive-patent-license-treatment-of-hermansky-pudlak-syndrome-and-idiopathic","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-24616?publication_date=2020-11-06","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-11-06/2020-24616/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":184,"last_updated":"2026-04-04 18:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-11-06/pdf/2020-24616.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-24616.pdf?1604583921","publication_date":"2020-11-06","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/11/06/2020-24616.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:39:37Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":71079,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis","toc_doc":"Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis","toc_subject":"Prospective Grant of Exclusive Patent License:\n","topics":[],"type":"Notice","volume":85}